HOUSTON, Feb. 18, 2020 /PRNewswire/ -- Marker
Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that its President and Chief Executive Officer,
Peter L. Hoang, will present at two
upcoming investor conferences.
Conference Details
Cowen 40th Annual Health Care Conference
Date:
Wednesday, March 4, 2020
Time: 8:40 a.m. ET
Location: Boston, MA
Oppenheimer 30th Annual Healthcare Conference
Date:
Wednesday, March 18, 2020
Time: 1:35 p.m. ET
Location: New York, NY
Live webcasts of the presentations will be accessible from
the investors section of the company's website
at markertherapeutics.com and will be available
for replay following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications. Marker's cell therapy
technology is based on the selective expansion of non-engineered,
tumor-specific T cells that recognize tumor associated antigens
(i.e. tumor targets) and kill tumor cells expressing those targets.
This population of T cells is designed to attack multiple tumor
targets following infusion into patients and to activate the
patient's immune system to produce broad spectrum anti-tumor
activity. Because Marker does not genetically engineer its T cell
therapies, we believe that our product candidates will be easier
and less expensive to manufacture, with reduced toxicities,
compared to current engineered CAR-T and TCR-based approaches, and
may provide patients with meaningful clinical benefit. As a result,
Marker believes its portfolio of T cell therapies has a compelling
product profile, as compared to current gene-modified CAR-T and
TCR-based therapies.
To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts
Forward-Looking Statement Disclaimer
This release
contains forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's
expectations, plans, business outlook or future performance, and
any other statements concerning assumptions made or expectations as
to any future events, conditions, performance or other matters, are
"forward-looking statements." Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our research, development and regulatory activities and
expectations relating to our non-engineered multi-tumor antigen
specific T cell therapies; the effectiveness of the MultiTAA
programs or the possible range of application and potential
curative effects and safety in the treatment of diseases;
expectations regarding our supplier's delivery of the final
reagent, data and certificate of analysis required to advance the
MultiTAA program for AML; and expectations regarding, among other
things, the timing, design and success of our clinical trials,
including the AML trial, as well as clinical trials conducted by
our collaborators. Forward-looking statements are by their nature
subject to risks, uncertainties and other factors which could cause
actual results to differ materially from those stated in such
statements. Such risks, uncertainties and factors include, but are
not limited to the risks set forth in the Company's most recent
Form 10-K, 10-Q and other SEC filings which are available through
EDGAR at www.sec.gov. The Company assumes no obligation to update
our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-two-upcoming-investor-conferences-301005624.html
SOURCE Marker Therapeutics, Inc.